Search research articles
Contact Us
Filters
Showing results (461-470 of 476) with videos related to
Page
of 48
Sort By:
Cancer
|
June 19, 2024
NPM1-mutated myeloid neoplasms are a unique entity not defined by bone marrow blast percentage
Georgina Gener-Ricos, Alex Bataller, Juan Jose Rodriguez-Sevilla, et al.
Cancer
|
December 2, 2022
A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia
Alexandre Bazinet, Faezeh Darbaniyan, Tapan M Kadia, et al.
Leukemia Research
|
August 23, 2024
Characteristics and outcomes of children, adolescent, and young adult patients with myelodysplastic neoplasms: A single-center retrospective analysis
David McCall, Tareq Abuasab, Juan Jose Rodriguez-Sevilla, et al.
Hematological Oncology
|
August 29, 2018
Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome
Christopher B Benton, Kelly S Chien, Ayalew Tefferi, et al.
Blood
|
July 13, 2023
Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia
Jayastu Senapati, Samuel Urrutia, Sanam Loghavi, et al.
The New England Journal of Medicine
|
August 13, 2015
A Randomized Trial of Intrapartum Fetal ECG ST-Segment Analysis
Michael A Belfort, George R Saade, Elizabeth Thom, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 1, 2024
Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax
Alexandre Bazinet, Sai Prasad Desikan, Ziyi Li, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 30, 2025
Outcomes of Patients With IDH1-Mutated Myeloid Neoplasms Treated With Olutasidenib
Kelly S Chien, Sanam Loghavi, Koji Sasaki, et al.
Journal of Hematology & Oncology
|
June 27, 2026
Vibecotamab for measurable residual disease in acute myeloid leukemia and for myelodysplastic syndromes and chronic myelomonocytic leukemia after hypomethylating agent failure: a phase II study
Nicholas J Short, Alex Bataller, Courtney D DiNardo, et al.
American Journal of Hematology
|
September 4, 2023
Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants
Alex Bataller, Sanam Loghavi, Yoheved Gerstein, et al.
Page
of 48
Search research articles
Search
Showing results (461-470 of 476) with videos related to
Sort By:
Page
of 48
Cancer
|
June 19, 2024
NPM1-mutated myeloid neoplasms are a unique entity not defined by bone marrow blast percentage
Georgina Gener-Ricos, Alex Bataller, Juan Jose Rodriguez-Sevilla, et al.
Cancer
|
December 2, 2022
A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia
Alexandre Bazinet, Faezeh Darbaniyan, Tapan M Kadia, et al.
Leukemia Research
|
August 23, 2024
Characteristics and outcomes of children, adolescent, and young adult patients with myelodysplastic neoplasms: A single-center retrospective analysis
David McCall, Tareq Abuasab, Juan Jose Rodriguez-Sevilla, et al.
Hematological Oncology
|
August 29, 2018
Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome
Christopher B Benton, Kelly S Chien, Ayalew Tefferi, et al.
Blood
|
July 13, 2023
Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia
Jayastu Senapati, Samuel Urrutia, Sanam Loghavi, et al.
The New England Journal of Medicine
|
August 13, 2015
A Randomized Trial of Intrapartum Fetal ECG ST-Segment Analysis
Michael A Belfort, George R Saade, Elizabeth Thom, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 1, 2024
Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax
Alexandre Bazinet, Sai Prasad Desikan, Ziyi Li, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 30, 2025
Outcomes of Patients With IDH1-Mutated Myeloid Neoplasms Treated With Olutasidenib
Kelly S Chien, Sanam Loghavi, Koji Sasaki, et al.
Journal of Hematology & Oncology
|
June 27, 2026
Vibecotamab for measurable residual disease in acute myeloid leukemia and for myelodysplastic syndromes and chronic myelomonocytic leukemia after hypomethylating agent failure: a phase II study
Nicholas J Short, Alex Bataller, Courtney D DiNardo, et al.
American Journal of Hematology
|
September 4, 2023
Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants
Alex Bataller, Sanam Loghavi, Yoheved Gerstein, et al.
Page
of 48